Cytokinetics Highlights Phase 3 Aficamten Data at ESC
SOUTH SAN FRANCISCO, Calif., Aug. 29, 2026 Cytokinetics, Incorporated announced additional clinical data for aficamten from the ACACIA-HCM and...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Device Medical Devices MedTech Monoclonal Antibody Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
SOUTH SAN FRANCISCO, Calif., Aug. 29, 2026 Cytokinetics, Incorporated announced additional clinical data for aficamten from the ACACIA-HCM and...
PRINCETON, N.J., August 26, 2026 Bristol Myers Squibb presented new long-term data for Camzyos® (mavacamten) at the European Society...
